FORM 3A - Director/Chief Executive Notice - Interests in Shares of Listed Corporation
 
Form Serial Number: DA20260618E00021
1. Date of relevant event: 10/06/2026
(dd/mm/yyyy)
2. Date when director became aware of the relevant event/ interest in the shares (if later):
(dd/mm/yyyy)
3. Stock code: 07630
4. Name of listed corporation: IMPACT Therapeutics, Inc - B - H Shares 
5. Class of shares: H Shares 
6. Number of issued shares in class: 282,461,530
7. Name of director (English) as printed on HKID Card/Passport:
(Surname) LIU
(Other names) Tao
10. Name of director (Chinese): 劉濤 
11. Chinese Character Code as printed on HKID Card:
 
24. Details of relevant event:
  Brief description of relevant event Capacity in which shares were/are held Number of shares bought/sold or involved Currency of transaction On Exchange Off Exchange
Before relevant event After relevant event Highest price (per share) Average price (per share) Average consideration (per share) Consideration code
Long position 
1710Miscellaneous
Voluntary disclosure (you must briefly describe the relevant event in the Supplementary Information box)
 
 
 		 7,921,202         
 
Short position 
 
 
 		            
 
25. Total shares in listed corporation immediately before the relevant event:
 Total number of sharesPercentage figure (%)
Long position7,921,2022.87
 
26. Total shares in listed corporation immediately after the relevant event:
 Total number of sharesPercentage figure (%)
Long position7,921,2022.80
 
27. Capacity in which interests disclosed in Box 26 are held:
Code describing capacityNumber of shares
2201Interest of corporation controlled by you
Long position7,921,202
 
28. Further information in derivative interests in listed corporation :
Derivatives code Exercise period (dd/mm/yyyy) Consideration - if derivatives granted by listed corporation Number of shares
  BeginsEndsCurrencyPrice for grantCurrencyExercise priceCurrencyPrice on assignment 
           
 
29. Further information in relation to interests of children under 18 and/or spouse:
Child/SpouseName of child/spouseNumber of shares
 
 
30. Further information in relation to interests of corporations controlled by Director:
Name of controlled corporationAddress and place of incorporationName of controlling person% controlDirect interest (Y/N)Number of shares
Shanghai China Summit Investment Management Co., Ltd. (上海華嶺投資管理有限公司)Room 344, Building 9, No. 450 Baoding Road, Hongkou District, Shanghai, ChinaTao LIU60.00N
Long position7,921,202
Shanghai China Summit Zhikang Health Investment Partnership (L.P.) (上海華嶺智康健康投資合夥企業(有限合夥))4th Floor (Central Registration Address), Nos. 391–393 (odd numbers) Dongdaming Road, Hongkou District, Shanghai, ChinaShanghai China Summit Investment Management Co., Ltd. (上海華嶺投資管理有限公司)60.00N
Long position4,362,991
Shanghai Hualing Zhikang Investment Management Co., Ltd. (上海華嶺智康投資管理有限公司)4th Floor (Central Registration Address), Nos. 391–393 (odd numbers) Dongdaming Road, Hongkou District, Shanghai, ChinaShanghai China Summit Investment Management Co., Ltd. (上海華嶺投資管理有限公司)60.00N
Long position4,362,991
Wuhan Biolake China Summit Fund Management Co., Ltd. (武漢光谷生物城華嶺基金管理有限公司)Building B1, R&D Buildings, Zones B, C, and D, Wuhan National Bioindustry Base Project, No. 666 Gaoxin Avenue, East Lake High-Tech Development Zone, Wuhan, Hubei, ChinaShanghai Hualing Zhikang Investment Management Co., Ltd. (上海華嶺智康投資管理有限公司)1.00N
Long position4,362,991
Wuhan Biolake China Summit Fund Partnership (Limited Partnership) (武漢光谷生物城華嶺基金合夥企業(有限合夥))Building B1, R&D Buildings, Zones B, C, and D, Wuhan National Bioindustry Base Project, No. 666 Gaoxin Avenue, East Lake High-Tech Development Zone, Wuhan, Hubei, ChinaShanghai China Summit Zhikang Health Investment Partnership (L.P.) (上海華嶺智康健康投資合夥企業(有限合夥))69.00Y
Long position4,362,991
Wuhan Biolake China Summit Fund Partnership (Limited Partnership) (武漢光谷生物城華嶺基金合夥企業(有限合夥))Building B1, R&D Buildings, Zones B, C, and D, Wuhan National Bioindustry Base Project, No. 666 Gaoxin Avenue, East Lake High-Tech Development Zone, Wuhan, Hubei, ChinaWuhan Biolake China Summit Fund Management Co., Ltd. (武漢光谷生物城華嶺基金管理有限公司)1.00Y
Long position4,362,991
Shanghai China Summit Zhixin Investment Partnership (LP) (上海華嶺智新投資合夥企業(有限合夥))Room 345, Building 9, No. 450 Baoding Road, Hongkou District, Shanghai, ChinaShanghai China Summit Investment Management Co., Ltd. (上海華嶺投資管理有限公司)90.00Y
Long position3,558,211
 
31. Further information in relation to interests held by Director jointly with another person:
Name of joint shareholderAddressNumber of shares
 
 
32. Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust:
Names of TrustAddressStatus codeNumber of shares
  
 
33. Further information from a party to an agreement under Section 317 (Please see Notes for further information required):
Names of other partiesAddressNumber of shares
 
Total number of shares in which a director is interested under sections 317 and 318
 
34. Supplementary information: Box24: On 10 June 2026, 6,296,400 H Shares of IMPACT Therapeutics, Inc were issued pursuant to the Over-allotment Option, and dealings in such Over-allotment Shares commenced on the Main Board of The Stock Exchange of Hong Kong Limited on 10 June 2026, as disclosed in the announcement of the Company dated 5 June 2026. As a result, the percentage level of interest held by Mr. Tao LIU (劉濤) has decreased.
35. Log/Serial Number of the previous form:
36. Number of concert party document(s) under section 317 attached/uploaded:
Date of filing this Form 3A: 18/06/2026
(dd/mm/yyyy)